BCL2L11 and cancer: Most recently, our previous study reported that targeting cathepsin K using siRNA or ODN enhances cancer cells’ sensitivity to sub-lethal doses of anti-cancer drugs by triggering pro-apoptotic protein Bim stabilization [12].